These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37721586)

  • 1. Oncological recurrence following pathological complete response after neoadjuvant treatment in patients with esophageal cancer - a retrospective cohort study.
    Hipp J; Kuvendjiska J; Hillebrecht HC; Herrmann S; Timme-Bronsert S; Fichtner-Feigl S; Hoeppner J; Diener MK
    Langenbecks Arch Surg; 2023 Sep; 408(1):363. PubMed ID: 37721586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study.
    Hipp J; Kuvendjiska J; Hillebrecht HC; Timme-Bronsert S; Fichtner-Feigl S; Hoeppner J; Diener MK
    Dis Esophagus; 2023 Jul; 36(7):. PubMed ID: 36572398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution.
    Lombardi PM; Pansa A; Basato S; Giorgi L; Perano V; Marano S; Castoro C
    Updates Surg; 2023 Jun; 75(4):921-930. PubMed ID: 36991302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?
    Meguid RA; Hooker CM; Taylor JT; Kleinberg LR; Cattaneo SM; Sussman MS; Yang SC; Heitmiller RF; Forastiere AA; Brock MV
    J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1309-17. PubMed ID: 19931663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
    Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
    Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment strategies in recurrent esophageal or junctional cancer.
    Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM
    Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nationwide validation of the prognostic impact of pathological response and the distribution of recurrence patterns in responders after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Matsuda S; Kitagawa Y; Kawakubo H; Okui J; Okamura A; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
    Esophagus; 2023 Apr; 20(2):205-214. PubMed ID: 36319809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.
    Jalilian M; Davis S; Mohebbi M; Sugamaran B; Porter IW; Bell S; Warrier SK; Wale R
    J Gastrointest Oncol; 2016 Aug; 7(4):603-8. PubMed ID: 27563451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
    Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
    Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.
    Urschel JD; Vasan H
    Am J Surg; 2003 Jun; 185(6):538-43. PubMed ID: 12781882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.